Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Kyverna Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 7.41 · gapped below the open, never looked back. High/low 7.40 at 4:00 am ET, 6.89 at 3:15 pm ET.
121 institutional managers report a position in Kyverna Therapeutics, Inc. worth $337.8M between them, filed on form 13F for the quarter ending 2026-06-30. 19 of them hold 80% of it, the largest being GordonMD Global Investments LP at 11.20%.
96 more managers in the register
19 managers hold 80% of the $337.8M institutional base. The other 102 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 77 days old and does not move with the price above it.
KYTX (Kyverna Therapeutics, Inc.) has 3 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
via Bain Capital Life Sciences Investors, LLC, Deerfield Management Co, Woodline Partners LP +1 more · 7.61% of KYTX, 8.10% of SVRA
via Gilead Sciences Inc, Woodline Partners LP, Wellington Management Group LLP · 10.88% of KYTX, 25.53% of RCUS
via GordonMD Global Investments LP, Woodline Partners LP · 11.20% of KYTX, 29.37% of PYXS
via Bain Capital Life Sciences Investors, LLC, Woodline Partners LP, Adage Capital Partners GP, L.L.C. +3 more · 7.61% of KYTX, 10.60% of CABA
via Gilead Sciences Inc, Woodline Partners LP, Qube Research & Technologies Ltd · 10.88% of KYTX, 26.48% of ASMB
via Gilead Sciences Inc · 10.88% of KYTX, 51.36% of LKFT
Managers holding a meaningful stake in KYTX also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.